– USA, CT – Precipio, Inc. (NASDAQ: PRPO), the specialty cancer diagnostics company,  today announced the appointment of veteran life sciences venture capitalist and executive Kathleen LaPorte to its board of directors as an independent member.

Ms. LaPorte will replace Dr. Michael Allen Luther who served on Transgenomic’s board since 2014 and remained as member of Precipio’s board since the merger in June 2017.

Ms. LaPorte is an executive and VC with 30 years experience building innovative life sciences companies. She served as general partner with Sprout Group from 1993-2004 and was one of the founders of New Leaf Venture Partners. She is a co-founder of Health Tech Capital, a group of healthcare technology focused private and corporate investors.

Ms. LaPorte served as chief business officer and later as CEO of Nodality, an immuno-oncology diagnostics company. She has served on numerous private and public company boards with roles on audit, compensation, and nominating committees.

Ms. LaPorte has a B.S. in biology from Yale University and an MBA from Stanford University Graduate School of Business.

“Precipio’s platform of potentially disruptive cancer diagnostics products and services is at a stage of growth that is a sweet spot for me,” commented Ms. LaPorte. “I’m excited about the potential to contribute to expediting the growth of the business.”

“Kathy’s experience is an ideal complement to the diverse expertise of our board and we are enthusiastic about the enhanced business potential derived from her uniquely relevant skills and network,” commented Ilan Danieli, Precipio CEO. “Furthermore, we are grateful to Mike for his years of service and guidance during the merger with Transgenomic, and the successful integration of the businesses during the past year.”

About Precipio

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

For more information : http://www.precipiodx.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.